Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITDAEPS (Basic)EPS (Weighted Average and Diluted)Income towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOther Operating ExpensesProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Summit Therapeutics (SMMT) Income from Continuing Operations (2016 - 2024)

Summit Therapeutics filings provide 11 years of Income from Continuing Operations readings, the most recent being 65623000.0 for Q4 2024.

  • Quarterly Income from Continuing Operations fell 81.23% to 65623000.0 in Q4 2024 from the year-ago period, while the trailing twelve-month figure was 234684000.0 through Dec 2024, up 61.51% year-over-year, with the annual reading at 234684000.0 for FY2024, 61.84% up from the prior year.
  • Income from Continuing Operations hit 65623000.0 in Q4 2024 for Summit Therapeutics, down from 60832000.0 in the prior quarter.
  • Across five years, Income from Continuing Operations topped out at 8999974.29 in Q1 2020 and bottomed at 537154000.0 in Q1 2023.
  • Average Income from Continuing Operations over 5 years is 53029398.71, with a median of 20395500.0 recorded in 2022.
  • The largest annual shift saw Income from Continuing Operations tumbled 2324.2% in 2023 before it soared 91.53% in 2024.
  • Summit Therapeutics' Income from Continuing Operations stood at 13541000.0 in 2020, then crashed by 100.13% to 27099000.0 in 2021, then grew by 25.09% to 20299000.0 in 2022, then plummeted by 78.38% to 36210000.0 in 2023, then plummeted by 81.23% to 65623000.0 in 2024.
  • Per Business Quant, the three most recent readings for SMMT's Income from Continuing Operations are 65623000.0 (Q4 2024), 60832000.0 (Q3 2024), and 62719000.0 (Q2 2024).